{"id":"NCT02617628","sponsor":"University of Pennsylvania","briefTitle":"Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone","officialTitle":"Improving Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone (Vivitrol) Before vs. After Reentry","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-01-01","primaryCompletion":"2018-12-31","completion":"2018-12-31","firstPosted":"2015-12-01","resultsPosted":"2020-04-15","lastUpdate":"2021-01-28"},"enrollment":146,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Opiate Dependence"],"interventions":[{"type":"DRUG","name":"extended release naltrexone","otherNames":["Vivitrol"]}],"arms":[{"label":"Before Re-entry","type":"ACTIVE_COMPARATOR"},{"label":"After Re-entry","type":"ACTIVE_COMPARATOR"}],"summary":"This study is a collaboration between the University of Pennsylvania, the Philadelphia Prison System, and the North East Treatment Center (NETSteps). It purpose is to study the impact of an injectable opiate addiction medication (extended release naltrexone) given before reentry into the community that might help to improve reconnection to healthcare and other support systems, and possibly help reduce recidivism.","primaryOutcome":{"measure":"Relapse to Opioid Use in Subjects by Month 3","timeFrame":"12 weeks (month 3)","effectByArm":[{"arm":"Before Re-entry","deltaMin":16,"sd":null},{"arm":"After Re-entry","deltaMin":20,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.38"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":11,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["37231479"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":74},"commonTop":["injection site reaction","anxiety","headache","depression","toothache"]}}